feedback

Course Director

David F. McDermott, MD
David F. McDermott, MD

Beth Israel Deaconess Medical Center
Dana-Farber Harvard Cancer Center Kidney Cancer Program
Harvard Medical School
Boston, Massachusetts

Faculty

Toni K. Choueiri
Toni K. Choueiri, MD

Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Daniel J. George
Daniel J. George, MD

Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC
Credit Amount:1.5 Credits
Release Date:2019-Mar-20
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, based on a recent live symposium held at the 2019 Genitourinary Cancers Symposium in San Francisco, experts in renal cell carcinoma (RCC) dip into their patient “CaseBook” to offer insights from their own practice on how best to bridge the divide between clinical research and daily care in the management of RCC. Pairing analysis of the latest evidence with application of key clinical concepts to decision-making in a complex therapeutic landscape, the expert panel explores how best to leverage the potency of newer agents across different RCC settings.

Upon completion of this activity, participants should be better able to:
  • Assess the latest evidence with and clinical implications of novel approaches, including new targeted agents, immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC)
  • Apply recently validated immunotherapy and targeted therapy options effectively for patients with advanced RCC that reflect optimal patient-centric selection and sequencing through multiple lines of therapy
  • Employ effective strategies to prevent and/or manage treatment-related complications with multi-targeted TKIs and immune checkpoint inhibitor therapy in patients with RCC
  • Recommend ongoing clinical trials assessing the latest therapies and/or combination approaches for advanced RCC patients in different disease settings

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologic oncologists, and other clinicians involved in the management of RCC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 20, 2019 - March 19, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC activity during the past 12 months.

Course Director and Moderator

David F. McDermott, MD
Director, Cutaneous and Immuno-Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David F. McDermott, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Array BioPharma; Bristol-Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech USA, Inc.; Jounce Therapeutics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and Pfizer Inc.
Grant/Research Support from Bristol-Myers Squibb and Prometheus Laboratories Inc.

David F. McDermott, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.

Faculty

Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
The Jerome and Nancy Kohlberg Endowed Chair
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Toni K. Choueiri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Alexion; Analysis Group; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; Cerulean Pharma Inc.; Corvus Pharmaceuticals; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Foundation Medicine, Inc.; Genentech, Inc.; GlaxoSmithKline; Heron Therapeutics, Inc.; Ipsen Pharma; Merck & Co., Inc.; National Comprehensive Cancer Network (NCCN); Novartis Pharmaceuticals Corporation; Peloton Pharmaceuticals Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; sanofi-aventis U.S. LLC; and Up-to-Date.
Grant/Research Support from Alexion; Analysis Group; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; Calithera; Cerulean Pharma Inc.; Corvus Pharmaceuticals; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Foundation Medicine, Inc.; Genentech, Inc.; GlaxoSmithKline; Ipsen Pharma; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Peloton Pharmaceuticals Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceuticals U.S.A., Inc.; and Tracon Pharmaceuticals, Inc. *Institution grants are being provided at faculty's request*
Honoraria from Alexion; American Society of Medical Oncology; Analysis Group; AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; Cerulean Pharma Inc.; Clinical Care Options; Corvus Pharmaceuticals; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Foundation Medicine, Inc.; Genentech, Inc.; GlaxoSmithKline; Harborside Press; Healthcare Communications Company (with several brands such as OnClive, PeerView and PER); Heron Therapeutics, Inc.; Ipsen Pharma; Kidney Cancer Journal; L-Path; Lancet Oncology; Merck & Co., Inc.; Michael J. Hennessy (MJH) Associates, Inc.; National Comprehensive Cancer Network (NCCN); Navinata Health, Inc.; New England Journal of Medicine (NEJM); Novartis Pharmaceuticals Corporation; Peloton Pharmaceuticals Inc.; Pfizer Inc.; PlatformQ, LLC; Prometheus Laboratories Inc.; sanofi-aventis U.S. LLC; and Up-to-Date. *CME activities are being included at faculty's request*
Other Financial or Material Support from Present or past leadership roles: Director of GU Oncology Division at Dana­ Farber and past President of Medical Staff at Dana-Farber; Member of NCCN Kidney Panel and the GU Steering Committee; Past Chairman of the Kidney Cancer Association Medical and Scientific Steering Committee.

Toni K. Choueiri, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.

Daniel J. George, MD
Professor of Medicine and Surgery
Director, GU Oncology
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Daniel J. George, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Astellas Pharma US, Inc.; Bayer Corporation; Bristol-Myers Squibb; Capio Biosciences; Exelixis, Inc.; Genentech, Inc.; Innocrin Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Myovant Sciences Ltd.; Pfizer Inc.; and sanofi-aventis U.S. LLC.
Grant/Research Support from Acerta Pharma; Astellas Pharma US, Inc.; Bayer Corporation; Bristol-Myers Squibb; Calithera; Dendreon Pharmaceuticals LLC; Exelixis, Inc.; Innocrin Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and sanofi-aventis U.S. LLC.
Speakers Bureau participant with Bayer Corporation; Exelixis, Inc.; and sanofi-aventis U.S. LLC.
Honoraria from EMD Serono, Inc.; Michael J Hennessey Associates; OncLive; Pfizer Inc.; and UroToday.
Other Financial or Material Support from Acceleron Pharma, Inc. and Janssen Pharmaceuticals, Inc. as part of an Independent Data Monitoring Committee (IDMC). Senior Editor for the American Association for Cancer Research. Serves as an independent contractor for Axess Oncology. Serves as the Co-Editor-in-Chief for the Millennium Medical Publishing, Clinical Advances in Hematology & Oncology. Steering Committee for Pfizer Inc. and National Cancer Institute (NCI).

Daniel J. George, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.

Content Reviewers

Teresa Haile, RPh, MBA, has no financial interests/relationships or affiliations in relation to this activity.

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Hamsa Jaganathan, PhD
PVI, PeerView Institute for Medical Education

Hamsa Jaganathan, PhD, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support from Spouse, consultant for Baxter, Becton Dickinson, and Sensyne Health.

Disclaimer

The information provided at this CME/MOC activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Providership


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by medical education grants from Exelixis, Inc., Merck & Co., Inc., and Prometheus Laboratories Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.